Sertraline Treatment of Pathological Gambling: A Pilot Study
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Several open-label and double-blind studies have suggested that selective serotonin reuptake inhibitors may be useful in the treatment of pathological gambling. The purpose of this study was to evaluate the efficacy of sertraline in the treatment of pathological gambling. METHOD: Sixty patients meeting the DSM-IV criteria for pathological gambling were treated for 6 months in a double-blind, flexible-dose, placebo-controlled study of sertraline 50 to 150 mg/day. Data were collected from November 1998 to January 2001. The primary outcome measure assessing change in clinical status was the responder rate with respect to the Criteria for Control of Pathological Gambling Questionnaire (CCPGQ). Secondary measures included the Clinical Global Impressions scale (CGI) (Severity of Illness and Improvement subscales), and Visual Analogue Scales assessing gambling frequency, severity, amount, and improvement. Concomitant medication and psychotherapy were not allowed during the study. RESULTS: At the end of the study, 23 sertraline-treated subjects (74%) and 21 placebo-treated subjects (72%) were considered as responders on the CCPGQ (p = .9). Similar results were obtained when the CGI-Improvement scale limited to symptoms of pathological gambling was used as an outcome measure. Sertraline was well tolerated throughout the study. CONCLUSION: Sertraline was not statistically significantly superior to placebo in the overall sample. The power of the study was limited by the high placebo-response rate and the small sample size.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.554 · Cited by 497
Leeman, R. F., & Potenza, M. N. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2550-7 · Cited by 448
Neural bases for addictive properties of benzodiazepines
Tan, K. R., Brown, M., Labouèbe, G., Yvon, C., Creton, C., Fritschy, J.-M., Rudolph, U., & Lüscher, C. (2010) · Nature · doi:10.1038/nature08758 · Cited by 397
Benzodiazepine Use and Misuse Among Adults in the United States
Maust, D. T., Lin, L. A., & Blow, F. C. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201800321 · Cited by 337
King, A. L. S., Valença, A. M., Silva, A. C., Sancassiani, F., Machado, S., & Nardi, A. E. (2014) · Clinical Practice & Epidemiology in Mental Health · doi:10.2174/1745017901410010028 · Cited by 336
Impulse Control Disorders: Updated Review of Clinical Characteristics and Pharmacological Management
Schreiber, L., Odlaug, B. L., & Grant, J. E. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00001 · Cited by 290
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
Behavioral Addictions as Mental Disorders: To Be or Not To Be?
Petry, N. M., Zajac, K., & Ginley, M. K. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045120 · Cited by 254
“In these studies, placebo response rates ranged from 31% (Grant et al. 2006) to 63% (Saiz-Ruiz et al. 2005), underscoring the need to include attention- and expectation-matched control conditions in psychotherapy trials as well.”
BackgroundThe Psychopathology and Treatment of Bipolar Disorder
Miklowitz, D. J., & Johnson, S. L. (2006) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.2.022305.095332 · Cited by 180
Torrens, M., Rossi, P. C., Martinez-Riera, R., Martinez-Sanvisens, D., & Bulbena, A. (2012) · Substance Use & Misuse · doi:10.3109/10826084.2012.663296 · Cited by 122
Continuation and Maintenance Use of Antidepressants in Recurrent Depression
Bockting, C. L. H., ten Doesschate, M. C., Spijker, J., Spinhoven, P., Koeter, M. W. J., & Schene, A. H. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000110056 · Cited by 121
Belleville, G. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500904 · Cited by 100
Pharmacological and psychosocial treatment of adults with gambling disorder: a meta-review
Di Nicola, M., De Crescenzo, F., D’Alò, G. L., Remondi, C., Panaccione, I., Moccia, L., Molinaro, M., Dattoli, L., Lauriola, A., Martinelli, S., et al. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000574 · Cited by 70
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D., & Dawson, G. R. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158303 · Cited by 66
Reynolds, L. M., Engin, E., Tantillo, G., Lau, H. M., Muschamp, J. W., Carlezon, W. A., & Rudolph, U. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.115 · Cited by 49
O'Connor, K., Marchand, A., Brousseau, L., Aardema, F., Mainguy, N., Landry, P., Savard, P., Léveillé, C., Lafrance, V., Boivin, S., et al. (2008) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.556 · Cited by 44
Engin, E., Bakhurin, K. I., Smith, K. S., Hines, R. M., Reynolds, L. M., Tang, W., Sprengel, R., Moss, S. J., & Rudolph, U. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.41 · Cited by 40
Jerrell, J., McIntyre, R., & Tripathi, A. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.3.2 · Cited by 31
Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety
Rickels, K., & Moeller, H. J. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1500031 · Cited by 30
Update on pathological gambling
Grant, J. E., Williams, K. A., & Kim, S. W. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0081-4 · Cited by 22
Metadata
- Authors
- Saiz-Ruiz, J., Blanco, C., Ibáñez, A., Masramon, X., Gómez, M. M., Madrigal, M., & Díez, T.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-01-15
- Volume
- 66
- Issue
- 01
- Pages
- 28-33
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1999104204
- Cited by
- 293
- References
- 0
- FWCI
- 22.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.